• Change of Visceral Fat Mass Assessed by Magnetic Resonance Imaging Scanning (MRI) [ Time Frame: Baseline, 52 weeks ] [ Designated as safety issue: No ]
  Fat measurements carried out with the subjects lying in a supine position in a MRI scanner. Measurements of regional body fat obtained between the level of the coccygeal bone and the 2nd or 3rd lumbar vertebra.
  
  

• Change in Visceral Fat Mass in Subgroups [ Time Frame: Baseline, 52 weeks, 78 weeks ] [ Designated as safety issue: No ]
  Change in visceral fat mass in subgroups. Subgroup 1: isolated GHD due to surgery and/or irradiation of pituitary adenoma and suprasellar tumors. Subgroup 2: history of traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH).
  
  
• Change From Baseline in Anthropometric Parameters (Height) [ Time Frame: Baseline, 52 weeks, 78 weeks ] [ Designated as safety issue: No ]
  
• Change From Baseline in Anthropometric Parameters (Weight) [ Time Frame: Baseline, 52 weeks, 78 weeks ] [ Designated as safety issue: No ]
  
• Change From Baseline in Anthropometric Parameters (Waist Circumference) [ Time Frame: Baseline, 52 weeks, 78 weeks ] [ Designated as safety issue: No ]
  
• Change From Baseline in Alertness (Testbatterie Zur Aufmerksamkeitsprüfung [TAP]) and Memory (Auditory Verbal Learning Test [AVLT]) [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: No ]
  Alertness: software-based neuropsychological assessment for response time and errors. Memory: analysis of learning and retention using 5-trial presentation of 15-word list (A), single presentation of interference list (B), 2 postinterference recall trials - 1 immediate, 1 delayed - and recognition of the target words with distractors (C). Performance variables were immediate word span under overload conditions, final acquisition level, amount learned in 5 trials, interference, delayed recall, and recognition (implicit learning).
  
  
• Change From Baseline in Blood Pressure [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: No ]
  Blood pressure was measured seated, the subject's arm supported at the level of the heart, and recorded to the nearest mm Hg. The same arm (preferably the dominant arm) was used throughout the trial. The subject was seated for 5 minutes before the blood pressure was obtained. Use of an automated device could have been used for measuring blood pressure.
  
  
• Change From Baseline in Heart Rate [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: No ]
  The use of an automated device for measuring pulse rate was acceptable, although, when done manually, pulse rate was measured in the brachial/radial artery for at least 30 seconds.
  
  
• Change in Executive Function and Memory in Subgroups [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: No ]
  Change in executive function and memory in subgroups. Subgroup 1: isolated Growth Hormone Deficiency (GHD)due to surgery and/or irradiation of pituitary adenoma and suprasellar tumors. Subgroup 2: history of traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH). Median reaction time, the total number of errors, the number of omissions and the number of false positive reactions.
  
  
• Change From Baseline in Safety Laboratory Assessments [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: Yes ]
  Prespecified safety laboratory assessments evaluated for change or no change from baseline. Possible responses were Yes/No.
  
  
• Change From Baseline in Homeostasis Model Assessment (HOMA)-Index [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: No ]
  HOMA index is calculated by 1 of 2 methods: HOMA-Index = fasting insulin measured in microunits per milliliter (µU/ml) times fasting glucose measured in milligrams per deciliter mg/dl) divided by 405 or HOMA-Index = fasting insulin (µU/ml) times fasting glucose measured in millimoles per liter (mmol/l) divided by 22.5.
  
  
• Change From Baseline in Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: No ]
  Participant self administered questionnaire consisting of 25 items that evoke yes or no answers. A score of 1 is given to each item affirmed and these are summed to give the total score. The maximum score is 25, which represents a poor quality of life. The minimum score is 0, which represents a good quality of life.
  
  
• Change From Baseline in Short Form (36) Health Survey (SF36) [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: No ]
  Participant self administered questionnaire that measures each of the following eight health concepts: Physical Functioning (PF); Role-Physical (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role-Emotional (RE); Mental Health (MH) as well as a reported Health Transition item (HT). Scale range 0 to 100, higher scores indicate a better health-related quality of life.
  
  
• Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: No ]
  Participant self-administered questionnaire EQ-5D, a 2 part generic health status instrument. The first part consists of 5 descriptors of current health state: mobility, self care, usual activities, pain/discomfort and anxiety/depression. Scores are assigned on a three-level scale (1= no problem, 2= some problem, 3= extreme problem). The second part was an overall rating of the participant's current health state using a 20 cm Visual Analogue Scale (EQ-VAS) with endpoints labelled 'best imaginable health state' and 'worst imaginable health state'.
  
  
• Change From Baseline in Cardiovascular Risk Factors [ Time Frame: Baseline, Week 52, Week 78 ] [ Designated as safety issue: No ]
  Change in values of laboratory tests indicative of possible cardiovascular risk factors: high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides, N-terminal pro brain natriuretic peptide)
  
  

The study was terminated on 15-Dec-2008 due to poor recruitment. Although 9 Patients were enrolled, no patient was randomized nor treated with somatropin. No safety reasons contributed to the termination.